US Thalidomide Survivors Seek Recognition Decades After Unapproved Drug Given to Pregnant Women

Americans born with thalidomide-related disabilities are demanding federal recognition, saying the government has long undercounted them.

Decades after one of history's most notorious pharmaceutical disasters, a group of Americans is still fighting to be officially acknowledged as victims. In the 1950s and 1960s, thalidomide — a sedative and anti-nausea drug — was given to pregnant women in the United States by doctors, even though the FDA never approved it for that use. Those women were often not told what they were receiving. Thalidomide causes severe birth defects when taken during pregnancy, particularly affecting limb development. Children born to mothers who took the drug frequently had malformed or missing arms and legs, as well as damage to internal organs, eyes, and ears. The drug became globally notorious after causing an estimated 10,000 or more birth defects worldwide, predominantly in Europe, where it was widely sold under brand names including Distilval and Contergan. The United States is widely credited with avoiding the worst of the thalidomide catastrophe because FDA reviewer Frances Kelsey refused to approve the drug for the American market, a decision later recognized as a landmark moment in drug-safety regulation. However, that narrative has obscured a quieter reality: thalidomide was distributed in the US through clinical trials and physician samples, meaning some pregnant American women did receive it. Now the children of those women — people now in their 60s, many living with limb differences and other disabilities — say the federal government has significantly undercounted how many of them exist. The official US figure has historically been cited as roughly 17 survivors, a number advocates call a vast underestimate. Survivors and researchers argue that because the drug was given covertly, without patient knowledge or consent, many cases were never recorded and many individuals never connected their conditions to thalidomide exposure. This group is seeking formal government recognition — both as validation of their experience and as a potential pathway to compensation and support services. They are aging, and many face increasing medical costs and physical challenges associated with their disabilities and the lifelong wear their bodies have experienced. Some European countries, including Germany and the United Kingdom, have provided compensation funds or ongoing support to their thalidomide survivors. The push for recognition carries a broader historical dimension as well. The thalidomide episode directly led to the 1962 Kefauver-Harris Amendment, which dramatically strengthened FDA oversight of drug approval and required manufacturers to prove both safety and efficacy before a drug could reach the market. That regulatory framework remains the foundation of US drug law today. Advocates say the survivors' struggle highlights how the celebrated story of American regulatory success left the people actually harmed on American soil without acknowledgment or recourse for over sixty years.

Why it matters

Thalidomide survivors in the US have spent their lives without formal recognition or the government support that counterparts in some other countries have received. Their aging and escalating care needs make the question of compensation and acknowledgment increasingly urgent.

What's next

Survivors and their advocates are pressing for a formal federal acknowledgment and potentially compensation, though no specific legislative action is cited in the reporting.

Key facts

• The FDA never approved thalidomide for use in the US, yet it was administered to pregnant women through clinical trials and physician samples in the 1950s and 1960s.
• The official US count of thalidomide survivors has been cited at roughly 17 — a figure survivors and researchers say is a significant undercount.
• Thalidomide caused an estimated 10,000 or more birth defects worldwide, primarily in Europe where it was commercially sold.
• Many American women who received thalidomide were not told they were taking it, meaning cases went unrecorded and survivors were never identified.
• FDA reviewer Frances Kelsey's refusal to approve thalidomide for the US market is credited with limiting the disaster, but did not prevent all domestic exposure.
• The thalidomide scandal directly prompted the landmark 1962 Kefauver-Harris Amendment, which required drug makers to prove safety and efficacy before FDA approval.

Bias & framing notes

All nine sources carry identical reporting from NPR — this is a single-origin story distributed across NPR member stations, so there is no independent corroboration from separate newsrooms. The framing is consistent across all outlets and centers sympathetically on survivors' perspectives; no government response or official counter-position is represented in the available reporting text.

NewsClear — neutral news & congressional tracking · Bill of the Week